Jennison Associates’s bluebird bio BLUE Stock Holding History

Jennison Associates’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-3,320	Closed	-$3.68M	–	666
2015 Q3	$3.68M	Buy	+3,320	New	+$6.05M	﹤0.01%	555

Other funds holding BLUE

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Jennison Associates's BLUE Position: Q1 2023 in Review

Jennison Associates sold out of bluebird bio (BLUE) in Q1 2023, closing a stake of 5,328 shares — an estimated $737K sold.

Jennison Associates first reported a position in BLUE in Q3 2013 and held it in 27 quarters. The position peaked at $96.3M in Q4 2017. 177 funds tracked by Wall St. Rank hold BLUE as of Q1 2023.

Jennison Associates reported no remaining bluebird bio position as of Q1 2023 after selling out during the quarter.
Jennison Associates sold 5,328 bluebird bio shares in Q1 2023, an estimated $737K.
Jennison Associates first reported a position in bluebird bio in Q3 2013 and held it in 27 quarters.
Jennison Associates's bluebird bio position peaked at $96.3M in Q4 2017.
177 funds tracked by Wall St. Rank held bluebird bio as of Q1 2023.

Based on Jennison Associates's 13F filing for Q1 2023, filed 26 Apr 2023.